Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L. A., Hui, K., & Farb, N. A. | Psychopharmacology | 2 January 2019
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L. A., Hui, K., ... & Farb, N. A. | Psychopharmacology | 2 January 2019
How do psychedelics work?
Carhart-Harris, R. L. | Current opinion in psychiatry | 1 January 2019
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression
Salloum, N. C., Fava, M., Freeman, M. P., Flynn, M., Hoeppner, B., Hock, R. S., & Mathew, S. J. | Depression and anxiety | 30 December 2018
Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects
Vizeli, P., Meyer zu Schwabedissen, H. E., & Liechti, M. E. | ACS chemical neuroscience | 27 December 2018
Effect of Ritualistic Consumption of Ayahuasca on Hepatic Function in Chronic Users.
Mello, S. M., Soubhia, P. C., Silveira, G., Corrêa-Neto, N. F., Lanaro, R., Costa, J. L., & Linardi, A. | Journal of psychoactive drugs | 22 December 2018
Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties.
Getachew, B., Aubee, J. I., Schottenfeld, R. S., Csoka, A. B., Thompson, K. M., & Tizabi, Y. | BMC microbiology | 22 December 2018
DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens
Lakstygal, A., Kolesnikova, T., Khatsko, S., Zabegalov, K., Volgin, A., Demin, K., & Kalueff, A. | ACS chemical neuroscience | 19 December 2018
Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter
Kuypers, K. P., de la Torre, R., Farré, M., Xicota, L., Perna, E. D. S. F., Theunissen, E. L., & Ramaekers, J. G. | Scientific reports | 18 December 2018
A Jamesian Response to Reductionism in the Neuropsychology of Religious Experience
Kime, K. G., & Snarey, J. R. | Archive for the Psychology of Religion | 13 December 2018
Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions.
Schenk, S., & Newcombe, D. | Journal of clinical psychopharmacology | 12 December 2018
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
Barsuglia, J. P., Davis, A. K., Palmer, R., Lancelotta, R., Windham-Herman, A. M., Peterson, K., ... & Griffiths, R. R. | Frontiers in psychology | 6 December 2018
3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats
Hake, H. S., Davis, J. K., Wood, R. R., Tanner, M. K., Loetz, E. C., Sanchez, A., ... & Greenwood, B. N. | Physiology & behavior | 4 December 2018
Classic Psychedelics: An integrative review of epidemiology, mystical experience, brain network function, and therapeutics
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. | Pharmacology & therapeutics | 4 December 2018
Psychiatry might need some psychedelic therapy
Johnson, M. W. | International Review of Psychiatry | 3 December 2018
Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence
Knuijver, T., Belgers, M., Markus, W., Verkes, R. J., van Oosteren, T., & Schellekens, A. | Journal of clinical psychopharmacology | 1 December 2018
Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans: Preliminary Evidence of Interactive Effects of Ayahuasca and Endocannabinoids in a Healthy Human Subject
dos Santos, R. G., Crippa, J. A., de Lima Osório, F., Rocha, J. M., Rossi, G. N., Marchioni, C., & Hallak, J. E. C. | Journal of clinical psychopharmacology | 1 December 2018
Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions.
Schenk, S., & Newcombe, D. | Journal of clinical psychopharmacology | December 2018
Monoamine biosynthesis via a noncanonical calcium-activatable aromatic amino acid decarboxylase in psilocybin mushroom
Torrens-Spence, M. P., Liu, C. T., Pluskal, T., Chung, Y. K., & Weng, J. K. | ACS chemical biology | 28 November 2018
Self-Experiments with Psychoactive Substances: A Historical Perspective
Passie, T., & Brandt, S. D. | Handbook of Experimental Pharmacology | 27 November 2018
The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial.
Yanakieva, S., Polychroni, N., Family, N., Williams, L. T., Luke, D. P., & Terhune, D. B. | Psychopharmacology | 26 November 2018
An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders
Renelli, M., Fletcher, J., Tupper, K. W., Files, N., Loizaga-Velder, A., & Lafrance, A. | Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity | 24 November 2018
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Garcia-Romeu, A., & Richards, W. A. | International Review of Psychiatry | 13 November 2018
Neuroimaging of chronic MDMA (“ecstasy”) effects: A meta-analysis
Müller, F., Brändle, R., Liechti, M. E., & Borgwardt, S. | Neuroscience & Biobehavioral Reviews | 12 November 2018
What Psilocybin Taught Me About Dying
Back, A. L. | Journal of palliative medicine | 9 November 2018